Reported results
- Operating revenue was $50.4 billion in 3Q 2026, up 0.7% from 3Q 2025.
- 3Q 2026 diluted EPS was $6.27 and adjusted diluted EPS was $6.99.
- The benefit expense ratio was 90.6 percent in the third quarter of 2026, an improvement of 70 basis points from the prior year quarter.
- The operating expense ratio was 11.4 percent and the adjusted operating expense ratio was 11.3 percent in 3Q 2026.
- Operating cash flow was $1.3 billion for the third quarter of 2026, up $0.1 billion relative to the prior year quarter.
Guidance
- FY 2026 diluted EPS guidance is at least $22.00.
- FY 2026 adjusted diluted EPS guidance is at least $29.00.
- FY 2026 operating cash flow guidance is at least $6.5 billion.
Notes
Results for the nine months ended September 30, 2026 include an accrual of $935 million ($4.28 per share) representing the current best estimate of identified potential exposure for certain historical Medicare Advantage risk adjustment data related to a CMS notice dated February 27, 2026.
Price and volatility reaction
The stock moved -1.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -8.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 440.18 | 2026-10-20 |
| Close after release | 434.13 | 2026-10-21 |
| Realised move | -1.4% | close to close |
| 30d ATM IV change | -8.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-21 (8-K, Item 2.02). Read the original filing on sec.gov.
